Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients. Review uri icon

Overview

abstract

  • With the advent new proteasome inhibitors (carfilzomib, ixazomib), new immune-modulatory drugs (pomalidomide), and new monoclonal antibodies (elotuzimab, daratumumab) as approved treatments for myeloma, the therapeutic landscape for this disease has changed. In this chapter, using a case-based approach, I will provide a personal guide of how I approach myeloma therapy in a transplant eligible patient in 2018.

publication date

  • November 30, 2018

Research

keywords

  • Multiple Myeloma

Identity

PubMed Central ID

  • PMC6245961

Scopus Document Identifier

  • 85058764617

Digital Object Identifier (DOI)

  • 10.1182/asheducation-2018.1.103

PubMed ID

  • 30504298

Additional Document Info

volume

  • 2018

issue

  • 1